51 - Outcomes of Cryoablation of Metastatic Musculoskeletal Lesions for Tumor Control

This study investigates the role of cryoablation in management of metastatic musculoskeletal lesions for tumor control.

Materials and Methods:

In this IRB approved single institution retrospective analysis, the medical records of patients who underwent cryoablation for tumor control of metastatic musculoskeletal lesions between June 2019 and June 2021 were reviewed. Patient demographics, oncologic diagnosis and prior oncologic treatments (systemic treatments, radiation) were reviewed. Ablation procedural details (location, size and appearance of the lesion, ablation duration, number of ablation positions) were reviewed, and follow up cross sectional imaging and clinic notes were reviewed to assess local tumor response, distant progression and procedural complications.

Results:

A total of 16 patients (10 males) with 20 lesions were included in the study. The median lesion size was 2.65 (IQR:2.1-3.7) cm. Ten lesions were lytic in appearance (10/20, 50%), 7 lesions were sclerotic and 3 were mixed. The median time to local tumor progression was 36.6 months (95%CI:5.3 – Not Reached) and the Local Tumor Progression-free survival rate was 56.4% at 1 year (95%CI:31.3-75.4%); 50.8% at 2 years (95%CI: 26.6-70.1%) and 50.8% at 3 years (95%CI: 26.6-70.1%). The median time to Distant Tumor progression was 6.2 months (95%CI:2.4-36.6). There were no major complications reported.

Conclusion:

Cryoablation is a safe and effective tool for local tumor control of metastatic musculoskeletal lesions.